74 dokter terbaik untuk pengobatan limfoma burkitt di dunia

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Elad Jacoby adalah pelopor terapi sel CAR-T pediatrik di Israel. Beliau mengepalai Pusat Terapi Sel Pediatrik di Sheba Medical Center. Dr. Jacoby berspesialisasi dalam menangani leukemia dan limfoma pediatrik yang kambuh dan berisiko tinggi. Beliau menyelesaikan fellowship di Johns Hopkins dan National Cancer Institute AS.

• Direktur Medis Pusat Bioterapi Lanjutan di Sheba Medical Center.
• Penulis lebih dari 240 publikasi ilmiah di bidang hemato-onkologi pediatrik.
• Bersertifikat dalam bidang Pediatri serta Hematologi dan Onkologi Pediatrik.
• Memimpin integrasi terapi sel CAR-T dengan transplantasi sumsum tulang.

Dr. Iris Kventsel adalah hemato-onkolog anak dan spesialis transplantasi sumsum tulang di Sheba Medical Center. Ia menangani sarkoma anak seperti sarkoma Ewing dan osteosarkoma di Rumah Sakit Anak Edmond dan Lily Safra. Dr. Kventsel mengintegrasikan terapi target dengan perawatan seluler untuk kanker anak yang kompleks. Ia bertugas sebagai staf akademik di Fakultas Kedokteran Universitas Tel Aviv.

• Spesialis dalam transplantasi sumsum tulang dan terapi sel CAR-T untuk pasien anak.
• Meneliti predisposisi genetik kanker, termasuk sindrom Li-Fraumeni dan gen kerentanan.
• Menerbitkan karya ilmiah di jurnal utama tentang biologi sel punca dan onkologi bedah (HIPEC).
• Bekerja di Sheba Medical Center, yang termasuk dalam 10 rumah sakit terbaik di dunia.

Dr. Hila Magen adalah hemato-onkolog Israel terkemuka di Sheba Medical Center. Beliau mengepalai Unit Mieloma Ganda dan Amiloidosis. Dr. Magen berspesialisasi dalam menangani kelainan sel plasma yang kompleks dan mieloma berisiko tinggi. Beliau adalah peneliti utama untuk program terapi CAR-T inovatif di tempat perawatan. Karyanya membawa imunoterapi canggih ke dalam perawatan klinis rutin.

• Menulis lebih dari 100 publikasi ilmiah dan studi penting tentang mieloma.
• Menyelesaikan fellowship di MD Anderson dan University of Arkansas for Medical Sciences.
• Melakukan terapi sel CAR-T dan transplantasi sumsum tulang.
• Bekerja di Sheba Medical Center, yang menduduki peringkat ke-7 di dunia pada tahun 2026 oleh Newsweek.

Spesialis onkohematologi, menangani kanker darah dan sistem limfatik di Assuta Medical Center.

• Berfokus secara eksklusif pada keganasan hematologi seperti limfoma Burkitt
• Menyediakan diagnosis ahli dan perencanaan perawatan untuk kanker darah yang kompleks
• Bekerja dalam jaringan rumah sakit Assuta yang terkenal di Israel

Lebih dari 3.500 transplantasi sumsum tulang telah dilakukan – Dr. Stepensky diakui oleh Forbes sebagai salah satu dokter terbaik.

• _doctor_3609_tahun_ praktik yang berspesialisasi dalam hematologi anak
• Pakar dalam merawat anak-anak dengan kanker darah langka seperti limfoma Burkitt
• Berpraktik di Hadassah Medical Center di Israel
• Dikenal karena tingkat keahlian yang tinggi dan perawatan yang penuh kasih

Profesor Zila Zuckerman adalah spesialis Hematologi dan Transplantologi yang berfokus pada kanker darah di Rambam Medical Center.

• Subspesialis transplantologi untuk kelainan darah
• Profesor akademik dengan keahlian tingkat penelitian
• Bekerja di pusat medis nasional terkemuka

Spesialis dalam pengobatan limfoma di Rambam Medical Center.

• Berfokus pada hematologi dengan pengalaman luas dalam kasus limfoma
• Bekerja di pusat medis terkemuka yang dikenal dengan perawatan onkologi
• Berdedikasi untuk menyediakan rencana perawatan yang dipersonalisasi bagi pasien

Pakar terkemuka dalam limfoma dan leukemia limfositik kronis – Profesor Bosch telah memelopori perawatan dan teknologi diagnostik baru untuk penyakit hematologi.

• Melakukan lebih dari 80 uji klinis dari fase 1 hingga fase 3
• Kepala Hematologi di IOB Institute of Oncology
• Menerbitkan lebih dari 100 artikel di jurnal terkemuka seperti NEJM dan Nature Medicine
• Presiden kelompok studi leukemia limfositik kronis Spanyol

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

Lebih dari 1.100 perawatan dilakukan – Prof. Elke Jaeger adalah ahli onkologi Jerman terkemuka yang berspesialisasi dalam limfoma Burkitt di Klinik Nordwest.

• 41 tahun pengalaman dalam onkologi klinis
• Kepala Onkologi dan Hematologi di Klinik Nordwest
• Diakui sebagai salah satu ahli onkologi terbaik di Jerman menurut peringkat Focus
• Berspesialisasi dalam kasus sarkoma yang kompleks

Prof. Dr. Rafet Eren berspesialisasi dalam hematologi dengan fokus kuat pada limfoma Burkitt, menggabungkan keahlian klinis dengan penelitian akademis.

• Lektor Kepala di bidang Hematologi dengan pengalaman luas
• 50+ publikasi di jurnal nasional dan internasional
• Anggota European Society of Hematology dan Turkish Hematology Association
• Penerima berbagai penghargaan untuk penelitian hematologi
• Fasih berbahasa Inggris, meningkatkan komunikasi dengan pasien

Dr. Apak telah berspesialisasi dalam hematologi-onkologi anak selama 26 tahun, dengan keahlian dalam transplantasi sumsum tulang dan terapi sel CAR T di Rumah Sakit Universitas Biruni.

• Kepala Hematologi-Onkologi Anak di Universitas Istanbul-Cerrahpaşa selama 26 tahun
• Menerbitkan 75 makalah internasional tentang onkologi anak
• Asisten editor untuk Turkish Pediatrics Archives Periodical
• Terlatih dalam kemoterapi leukemia dan terapi tingkat lanjut

Dr. Eckhart Weidmann memimpin sektor Hematologi di Klinik Nordwest dengan pengalaman lebih dari _doctor_501_ tahun dalam menangani kelainan darah.

• Berspesialisasi dalam pengobatan limfoma non-Hodgkin
• Profesor dengan keahlian akademik dan klinis yang luas
• Berdedikasi untuk menangani kondisi hematologi yang kompleks

Prof. Dr. Serdar Bedii Omay telah menerbitkan lebih dari 65 artikel ilmiah tentang hematologi dan transplantasi sumsum tulang, dengan pengalaman luas di institusi-institusi terkemuka.

• Spesialis hematologi di Fakultas Kedokteran Mie, Jepang
• Profesor Hematologi di Universitas Ege dan Universitas Teknik Karadeniz
• Lebih dari _doctor_2835_tahun_ pengalaman di bidang hematologi
• Menerbitkan 112 makalah pertemuan dan 34 presentasi konferensi

Prof. Baytan berspesialisasi dalam kanker anak, dengan fokus kuat pada limfoma Burkitt dan leukemia di Rumah Sakit Emsey.

• _doctor_2836_tahun_ pengalaman dalam hematologi pediatrik
• Menerbitkan 15 artikel di jurnal medis internasional
• Pakar dalam diagnosis dan pengobatan penyakit pendarahan pada anak
• Mantan Asisten Profesor di Universitas Uludağ

Dr. Kadri Yamac adalah seorang internis dan hematolog. Beliau memperoleh gelar kedokteran dari Fakultas Kedokteran Universitas Ankara (1976–1982). Beliau menyelesaikan pelatihan Penyakit Dalam di Fakultas Kedokteran Universitas Gazi (1984–1989). Kemudian, beliau menyelesaikan subspesialisasi Hematologi di Fakultas Kedokteran Universitas Gazi (1990–1993). Beliau menjadi Lektor Kepala di Fakultas Kedokteran Universitas Gazi pada tahun 1995. Beliau dipromosikan menjadi Profesor pada tahun 2002.

Minat medis: anemia, gangguan koagulasi, hemokromatosis, leukemia limfositik kronis, penyakit kelenjar getah bening, limfoma non-Hodgkin, limfoma Hodgkin.